Back

Are allergic diseases a risk factor for systemic side effects after COVID-19 vaccines?

ATAYIK, E.; Aytekin, G.

2022-01-24 allergy and immunology
10.1101/2022.01.23.22269704 medRxiv
Show abstract

Background/ aimMass vaccination seems to be the most effective way to turn back to the pre-pandemic period and end the pandemic. Unfortunately, COVID-19 vaccines have some side effects. In phase studies of currently-approved COVID-19 vaccines, patients with a known allergy or a history of anaphylaxis were excluded from the studies. This situation creates doubts about the course of atopy and the presence of allergic disease related to the side effects of COVID-19 vaccines in patients with allergic diseases. Therefore, our aim with this study was to evaluate local side effects (LSE) and systemic side effects (SSE) after COVID-19 vaccines in patients with allergic diseases and to determine possible risk factors. Materials and MethodsSix hundred forty-eight adult patients who received any COVID-19 vaccine between April 1, 2021 and September 30, 2021 and agreed to participate in the study were included in this case-control retrospective study. ResultsSix hundred forty-eight adult patients [Female: 446 (68.8%), Male: 202 (32.2%)] participated in the study. After the 1st dose of COVID-19 vaccine, 24.1% of patients reported SSE. After the 2nd dose of COVID-19 vaccine, 67 patients (12.3%) developed SSE. Female gender (OR: 1.757, 95%Cl: 1.143-2.702, p: 0.010), history of previous COVID-19 infection (OR: 1.762, 95%Cl: 1.068-2.906, p: 0.026), and COVID-19 vaccine type administered (OR: 4.443, 95% CI: 2.640-7.476, p<0.001) were found to be independent risk factors for SSE after COVID-19 vaccines. Premedication (OR: 0.454, 95% Cl: 0.281-0.733, p<0.001), was found to be a protective factor for SSE developing after COVID-19 vaccines. ConclusionCoronoVac and Pfizer-BioNTech COVID-19 vaccines are shown to be well tolerated. Patients with allergic disease do not have an increased risk for SSE that may develop after COVID-19 vaccines. Moreover, doubts or fears about possible side effects in the allergic patient group should not be an obstacle to COVID-19 vaccination.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Vaccines
198 papers in training set
Top 0.1%
19.0%
2
Vaccine
203 papers in training set
Top 0.3%
12.2%
3
PLOS ONE
5266 papers in training set
Top 21%
8.1%
4
Immunology
28 papers in training set
Top 0.1%
8.1%
5
Journal of Medical Virology
140 papers in training set
Top 0.2%
6.4%
50% of probability mass above
6
Medicine
31 papers in training set
Top 0.2%
5.0%
7
Allergy
25 papers in training set
Top 0.1%
4.4%
8
Frontiers in Immunology
638 papers in training set
Top 4%
3.3%
9
Archives of Clinical and Biomedical Research
28 papers in training set
Top 0.1%
3.3%
10
Journal of Clinical Medicine
97 papers in training set
Top 1%
2.7%
11
Pharmaceuticals
34 papers in training set
Top 0.3%
2.2%
12
Heliyon
152 papers in training set
Top 3%
2.0%
13
Open Forum Infectious Diseases
142 papers in training set
Top 2%
1.2%
14
Scientific Reports
3612 papers in training set
Top 63%
1.2%
15
Cureus
68 papers in training set
Top 4%
0.9%
16
Journal of Infection and Public Health
15 papers in training set
Top 0.3%
0.9%
17
eClinicalMedicine
77 papers in training set
Top 2%
0.9%
18
IJID Regions
11 papers in training set
Top 0.4%
0.6%
19
Diagnostics
50 papers in training set
Top 3%
0.6%
20
Microbial Pathogenesis
17 papers in training set
Top 0.5%
0.6%
21
Infectious Diseases of Poverty
11 papers in training set
Top 0.4%
0.6%
22
Drug Safety
10 papers in training set
Top 0.3%
0.6%
23
Archives of Public Health
14 papers in training set
Top 0.7%
0.6%